Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Trodelvy“
Suchtreffer
Begriffe & Kennungen
Trodelvy · 4.8 · Adverse reactions occurring in patients treated with sacituzumab govitecan in combination with pembrolizumab w
Eintrag öffnenTrodelvy · 4.8 · Compared to patients homozygous for the wild-type allele, earlier median onset of neutropenia and anaemia was
Eintrag öffnenTrodelvy · 4.8 · Description of selected adverse reactions
Eintrag öffnenTrodelvy · 4.8 · Diarrhoea The median time to onset of diarrhoea following the start of the first treatment cycle was 13 days.
Eintrag öffnenTrodelvy · 4.8 · Diarrhoea occurred in 59.9% of patients treated with sacituzumab govitecan. Grade 3 events occurred in 10.0% o
Eintrag öffnenTrodelvy · 4.8 · Febrile neutropenia occurred in 5.6% of patients treated with sacituzumab govitecan. Febrile neutropenia was t
Eintrag öffnenTrodelvy · 4.8 · Hypersensitivity Hypersensitivity reactions reported up to the end of the day following dosing occurred in 12.
Eintrag öffnenTrodelvy · 4.8 · Immunogenicity Across clinical studies in patients treated with sacituzumab govitecan, 13 (1.2%) of 1058 patie
Eintrag öffnenTrodelvy · 4.8 · Neutropenia The median time to onset of neutropenia (including febrile neutropenia) following the start of the
Eintrag öffnenTrodelvy · 4.8 · Neutropenia occurred in 67.3% of patients treated with sacituzumab govitecan, including Grade 3-4 neutropenia
Eintrag öffnenTrodelvy · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenTrodelvy · 4.8 · Sacituzumab govitecan as monotherapy
Eintrag öffnenTrodelvy · 4.8 · Sacituzumab govitecan in combination with pembrolizumab
Eintrag öffnenTrodelvy · 4.8 · Special Populations There was a higher discontinuation rate due to adverse reactions in patients aged 65 years
Eintrag öffnenTrodelvy · 4.8 · Summary of the safety profile
Eintrag öffnenTrodelvy · 4.8 · System organ class Monotherapy In combination with pembrolizumab (SOC) and Frequency Infections and infestatio
Eintrag öffnenTrodelvy · 4.8 · Table 3: List of adverse reactions
Eintrag öffnenTrodelvy · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenTrodelvy · 4.8 · The combination of sacituzumab govitecan with pembrolizumab did not increase the frequency or severity of pemb
Eintrag öffnenTrodelvy · 4.8 · The data below reflect information for significant adverse reactions for sacituzumab govitecan as monotherapy
Eintrag öffnen